We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Caprion Announces Biomarker Discovery Collaboration with Berlex
News

Caprion Announces Biomarker Discovery Collaboration with Berlex

Caprion Announces Biomarker Discovery Collaboration with Berlex
News

Caprion Announces Biomarker Discovery Collaboration with Berlex

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Caprion Announces Biomarker Discovery Collaboration with Berlex"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Caprion Pharmaceuticals Inc. has announced research collaboration with Berlex Inc., a US affiliate of Schering AG Germany. 

The collaboration will use Caprion’s CellCarta® proteomics platform to support biomarker discovery. Caprion will identify pharmacodynamic biomarkers in plasma resulting from the administration of Berlex compounds in pre-clinical development.

"Caprion is looking forward to working with Berlex on their pre-clinical therapeutic candidates," noted Dr. Daniel Chelsky, Chief Scientific Officer at Caprion.

"We believe Caprion’s capabilities in the discovery of protein biomarkers will significantly impact our partner’s development efforts."

Caprion’s proprietary proteomics platform profiles the expression and identity of proteins detected in tissues and blood plasma.

Advertisement